Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet. 2020;396(10266):1915–1926

CAS  PubMed  Google Scholar 

You H, Ma X, Efe C, et al. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int. 2022;16(1):1–23

PubMed  Google Scholar 

Hirschfield GM, Beuers U, Corpechot C, Invernizzi P, Jones D, Marzioni M. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172

Google Scholar 

Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71(2):357–365

CAS  PubMed  Google Scholar 

Gatselis NK, Goet JC, Zachou K, et al. Factors associated with progression and outcomes of early stage primary biliary cholangitis. Clin Gastroenterol Hepatol. 2020;18(3):684-692.e6

CAS  PubMed  Google Scholar 

Yang Y, He X, Rojas M, Leung PSC, Gao L. Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis? Front Immunol. 2023. https://doi.org/10.3389/fimmu.2023.1184252

Article  PubMed  PubMed Central  Google Scholar 

Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871–877

CAS  PubMed  Google Scholar 

EASL Clinical Practice Guidelines. The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172

Google Scholar 

Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361–1367

CAS  PubMed  Google Scholar 

Kuiper EMM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136(4):1281–1287

CAS  PubMed  Google Scholar 

Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(10):2186–2194

CAS  PubMed  Google Scholar 

Ding D, Guo G, Cui L, et al. Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria. Hep Intl. 2024;18(1):206–215

Google Scholar 

Corpechot C, Carrat F, Gaouar F, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol. 2022;77(6):1545–1553

PubMed  Google Scholar 

Ding D, Guo G, Liu Y, et al. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. Hepatol Commun. 2022;6(12):3487–3495

CAS  PubMed  PubMed Central  Google Scholar 

Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China. Gastroenterology. 2023;165(4):1025–1040

PubMed  Google Scholar 

Ding D, Hu Y, Jia G, et al. Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment. Hepatol Int. 2024. https://doi.org/10.1007/s12072-024-10743-w

Article  PubMed  Google Scholar 

Ding D, Xuan G, Hu Y, et al. Immunoglobulin M: a neglected serum biomarker in treatment-naive primary biliary cholangitis with normal alkaline phosphatase. Hepatol Commun. 2022;6(6):1403–1412

CAS  PubMed  PubMed Central  Google Scholar 

Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56(1):198–208

PubMed  Google Scholar 

Murillo Perez CF, Hirschfield GM, Corpechot C, et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther. 2019;50(10):1127–1136

CAS  PubMed  Google Scholar 

Corpechot C, Lemoinne S, Soret P, et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology. 2024;79(1):39–48

PubMed  Google Scholar 

Roberts SB, Choi WJ, Worobetz L, et al. Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis. JHEP Rep. 2024;6(10): 101168

PubMed  PubMed Central  Google Scholar 

Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149(7):1804-1812.e4

PubMed  Google Scholar